OBJECTIVE: To investigate the role of the apolipoprotein E (APOE) locus in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). DESIGN: Case-control study. SETTING: Neurology clinic, Rome, Italy. PATIENTS: Eighty-six patients with a clinical diagnosis of sporadic FTD, including 32 patients with a clinical diagnosis of PPA, and 99 nondemented cognitively intact control subjects. MAIN OUTCOME MEASURES: Genotype analysis of the 3 single-nucleotide polymorphisms rs449647, rs769446, and rs405509 in the promoter region of the APOE gene and of the 2 single-nucleotide polymorphisms rs429358 and rs7412 forming the common apoE polymorphism. RESULTS: Significant associations with FTD were observed for genotypes rs449647 A/T (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.0-4.5), rs769446 T/C (OR, 4.4; 95% CI, 1.9-10.2), and APOE ε3/ε4 (OR, 4.1; 95% CI, 1.6-10.9). Significant associations with PPA were also observed for genotypes APOE ε3/ε4 (OR, 22.5; 95% CI, 1.2-229.4) and ε4/ε4 (OR, 7.5; 95% CI, 2.6-21.6). Significant associations with FTD were observed for haplotypes A-C-G-C-C (OR, 5.6; 95% CI, 1.4-21.5) and T-T-T-C-C (OR, 5.2; 95% CI, 1.1-24.0). Significant associations with PPA were also observed for haplotypes A-T-T-T-C (OR, 0.4; 95% CI, 0.2-0.9) and A-T-T-C-C (OR, 5.2; 95% CI, 1.4-19.3). CONCLUSION: Although the physiological role of apoE in FTD and PPA needs further investigations, our results suggest an involvement of the APOE gene locus in the genetics of FTD and PPA.
OBJECTIVE: To investigate the role of the apolipoprotein E (APOE) locus in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). DESIGN: Case-control study. SETTING: Neurology clinic, Rome, Italy. PATIENTS: Eighty-six patients with a clinical diagnosis of sporadic FTD, including 32 patients with a clinical diagnosis of PPA, and 99 nondemented cognitively intact control subjects. MAIN OUTCOME MEASURES: Genotype analysis of the 3 single-nucleotide polymorphisms rs449647, rs769446, and rs405509 in the promoter region of the APOE gene and of the 2 single-nucleotide polymorphisms rs429358 and rs7412 forming the common apoE polymorphism. RESULTS: Significant associations with FTD were observed for genotypes rs449647 A/T (odds ratio [OR], 2.1; 95% confidence interval [CI], 1.0-4.5), rs769446 T/C (OR, 4.4; 95% CI, 1.9-10.2), and APOE ε3/ε4 (OR, 4.1; 95% CI, 1.6-10.9). Significant associations with PPA were also observed for genotypes APOE ε3/ε4 (OR, 22.5; 95% CI, 1.2-229.4) and ε4/ε4 (OR, 7.5; 95% CI, 2.6-21.6). Significant associations with FTD were observed for haplotypes A-C-G-C-C (OR, 5.6; 95% CI, 1.4-21.5) and T-T-T-C-C (OR, 5.2; 95% CI, 1.1-24.0). Significant associations with PPA were also observed for haplotypes A-T-T-T-C (OR, 0.4; 95% CI, 0.2-0.9) and A-T-T-C-C (OR, 5.2; 95% CI, 1.4-19.3). CONCLUSION: Although the physiological role of apoE in FTD and PPA needs further investigations, our results suggest an involvement of the APOE gene locus in the genetics of FTD and PPA.
Authors: Isabel Hernández; Ana Mauleón; Maiteé Rosense-Roca; Montserrat Alegret; Georgina Vinyes; Anna Espinosa; Oscar Sotolongo-Grau; James T Becker; Sergi Valero; Lluís Tarraga; Oscar L López; Agustín Ruiz; Mercè Boada Journal: Curr Alzheimer Res Date: 2014-02 Impact factor: 3.498
Authors: Kimiko Domoto-Reilly; Marie Y Davis; C Dirk Keene; Thomas D Bird Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-03-16 Impact factor: 3.568
Authors: Anahita Adeli; Rodolfo Savica; Val J Lowe; Prashanthi Vemuri; David S Knopman; Mariely Dejesus-Hernandez; Rosa Rademakers; Julie A Fields; Brian A Crum; Clifford R Jack; Ronald C Petersen; Bradley F Boeve Journal: Neurocase Date: 2012-11-30 Impact factor: 0.881
Authors: Walter Maetzler; Anja Apel; Markus Langkamp; Christian Deuschle; Sarah Selina Dilger; Johannes Georg Stirnkorb; Claudia Schulte; Erwin Schleicher; Thomas Gasser; Daniela Berg Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240